The interferon signature in autoimmune diseases

Current Opinion in Rheumatology

Volumn 25, Issue 2, 2013, Pages 248-253

  Rönnblom, Lars ^a   Eloranta, Maija Leena ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

autoimmune disease; IFN regulated gene expression; interferon signature; type I interferon

Indexed keywords

AGS 009; ALPHA INTERFERON; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; DNA; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON; INTERFERON ANTIBODY; INTERLEUKIN 28; INTERLEUKIN 29; RNA; RONTALIZUMAB; SIFALIMUMAB; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN A;

AICARDI GOUTIERES SYNDROME; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL PROLIFERATION; DISCOID LUPUS ERYTHEMATOSUS; HUMAN; INTERFERON PRODUCTION; KILLER CELL; LYMPHOCYTE; MYOSITIS; NATURAL KILLER CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE; UPREGULATION;

AUTOIMMUNE DISEASES; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERFERONS; RHEUMATIC DISEASES; SIGNAL TRANSDUCTION;

EID: 84873404949     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32835c7e32     Document Type: Review

References (52)

1. van Baarsen LG, Bos CL, van der Pouw Kraan TC, Verweij CL. Transcription profiling of rheumatic diseases. Arthritis Res Ther 2009; 11:207.
2. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197:711-723.
3. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100:2610-2615.
4. Crow MK, Wohlgemuth J. Microarray analysis of gene expression in lupus. Arthritis Res Ther 2003; 5:279-287.
5. Higgs BW, Liu Z, White B, et al. Patientswith systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011; 70:2029-2036.
6. Ruiz-Riol M, Barnils Mdel P, Colobran Oriol R, et al. Analysis of the cumulative changes in Graves' disease thyroid glands points to IFN signature, plasma-cytoid DCsand alternativelyactivated macrophagesaschronicitydetermining factors. J Autoimmun 2011; 36:189-200.
7. Krause I, Shoenfeld Y. Intravenous immunoglobulin treatment for fibrosis, atherosclerosis, and malignant conditions. Methods Mol Med 2005; 109:403-408.
8. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, et al. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 2011; 17: 2619-2627.
9. O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 2012; 36:542-550.
10. Hertzog P, Forster S, Samarajiwa S. Systems biology of interferon responses. J Interferon Cytokine Res 2011; 31:5-11.
11. Forster S. Interferon signatures in immune disorders and disease. Immunol Cell Biol 2012; 90:520-527.
12. Rönnblom L, Alm GV, Eloranta ML. The type I interferon system in the development of lupus. Semin Immunol 2011; 23:113-121.
13. Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007; 449:564-569.
14. Bronson PG, Chaivorapol C, Ortmann W, et al. The genetics of type I interferon in systemic lupus erythematosus. Curr Opin Immunol 2012; 24:530-537.
15. Sigurdsson S, Nordmark G, Göring HH, et al. Polymorphisms in the tyrosine kinase 2and interferon regulatoryfactor5 genesareassociatedwith systemic lupus erythematosus. Am J Hum Gen 2005; 76:528-537.
16. Feng D, Stone RC, Eloranta ML, et al. Genetic variants and disease-asso-ciated factors contribute to enhanced interferon regulatory factor 5 expres-sion in blood cells of patients with systemic lupus erythematosus. Arthritis Rheum 2010; 62:562-573.
17. Stone RC, Feng D, Deng J, et al. Interferon regulatory factor 5 activation in monocytes of systemic lupus erythematosus patients is triggered by circulating autoantigens independent of type I interferons. Arthritis Rheum 2012; 788-798.
18. Niewold TB, Kelly JA, Kariuki SN, et al. IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythe-matosus. Ann Rheum Dis 2012; 71:463-468.
19. Wang C, Sandling JK, Hagberg N, et al. Genome-wide profiling of target genes for the systemic lupus erythematosus-associated transcription factors IRF5 and STAT4. Ann Rheum Dis 2012. [Epub ahead of print]
20. Kariuki SN, Kirou KA, MacDermott EJ, et al. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol 2009; 182:34-38.
21. Robinson AB, Thierry-Palmer M, Gibson KL, Rabinovich CE. Disease activity, proteinuria, and vitamin D status in children with systemic lupus erythema-tosus and juvenile dermatomyositis. J Pediatr 2012; 160:297-302.
22. Elkon KB, Wiedeman A. Type I IFN system in the development and manifesta-tions of SLE. Curr Opin Rheumatol 2012; 24:499-505.
23. Eloranta ML, Lövgren T, Finke D, et al. Regulation of the interferon-alpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum 2009; 60:2418-2427.
24. Berggren O, Hagberg N, Weber G, et al. B lymphocytes enhance the interferon-alpha production by plasmacytoid dendritic cells. Arthritis Rheum 2012; 64:3409-3419.
25. Lood C, Gullstrand B, Truedsson L, et al. C1q inhibits immune complex-induced interferon-alpha production in plasmacytoid dendritic cells: a novel link between C1q deficiency and systemic lupus erythematosus pathogenesis. Arthritis Rheum 2009; 60:3081-3090.
26. Santer DM, Hall BE, George TC, et al. C1q deficiency leads to the defective suppression of IFN-alpha in response to nucleoprotein containing immune complexes. J Immunol 2010; 185:4738-4749.
27. Gordon RA, Grigoriev G, Lee A, et al. The interferon signature and STAT1 expression in rheumatoid arthritis synovial fluid macrophages are induced by tumor necrosis factor alpha and counter-regulated by the synovial fluid microenvironment. Arthritis Rheum 2012; 64:3119-3128.
28. Li J, Fu Q, Cui H, et al. Interferon-alpha priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-alpha and atherosclerosis in lupus. Arthritis Rheum 2011; 63:492-502.
29. Denny MF, Thacker S, Mehta H, et al. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 2007; 110:2907-2915.
30. Thacker SG, Berthier CC, Mattinzoli D, et al. The detrimental effects of IFN-alpha on vasculogenesis in lupus are mediated by repression of IL-1 path-ways: potential role in atherogenesis and renal vascular rarefaction. J Immunol 2010; 185:4457-4469.
31. Santer DM, Yoshio T, Minota S, et al. Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. J Immunol 2009; 182:1192-1201.
32. Hjelmervik TO, Petersen K, Jonassen I, et al. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome pa-tients from healthy control subjects. Arthritis Rheum 2005; 52:1534-1544.
33. Landolt-Marticorena C, Bonventi G, Lubovich A, et al. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis 2009; 68: 1440-1446.
34. Petri M, Singh S, Tesfasyone H, et al. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 2009; 18:980-989.
35. Bauer JW, Petri M, Batliwalla FM, et al. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 2009; 60:3098-3107.
36. Bauer JW, Baechler EC, Petri M, et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006; 3:e491.
37. Morimoto AM, Flesher DT, Yang J, et al. Association of endogenous anti-interferon-alpha autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63:2407-2415.
38. Braunstein I, Klein R, Okawa J, Werth VP. The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity indexscore. Br J Dermatol 2012; 166:971-975.
39. Zahn S, Rehkamper C, Kummerer BM, et al. Evidencefora pathophysiological role of keratinocyte-derived type III interferon (IFNlambda) in cutaneous lupus erythematosus. J Invest Dermatol 2011; 131:133-140.
40. Yin Z, Dai J, Deng J, et al. Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J Immunol 2012; 189:2735-2745.
41. van Baarsen LG, Wijbrandts CA, Rustenburg F, et al. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther 2010; 12:R11.
42. van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment ofatype I interferon signature in asubpopulation ofpatients. Ann Rheum Dis 2007; 66:1008-1014.
43. Mavragani CP, La DT, Stohl W, Crow MK. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc ana-lysis of a predominantly Hispanic cohort. Arthritis Rheum 2010; 62: 392-401.
44. Reynier F, Petit F, Paye M, et al. Importance of correlation between gene expression levels: application to the type I interferon signature in rheumatoid arthritis. PLoS One 2011; 6:e24828.
45. Lyons PA, McKinney EF, Rayner TF, et al. Novel expression signatures identified by transcriptional analysis of separated leucocyte subsets in sys-temic lupus erythematosus and vasculitis. Ann Rheum Dis 2010; 69:1208-1213.
46. Brkic Z, Maria NI, van Helden-Meeuwsen CG, et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis [Epub ahead of print]
47. Lichtman EI, Helfgott SM, Kriegel M.A. Emerging therapies for systemic lupus erythematosus: focus on targeting interferon-alpha. Clin Immunol 2012; 143:210-221.
48. Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human antiinterferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind rando-mised study. Ann Rheum Dis 2011; 70:1905-1913.
49. McBride JM, Jiang J, Abbas AR, et al. Safety and pharmacodynamic results of rontalizumab in a phase i, placebo controlled, double blind, dose escalation study in systemic lupus erythematosus. Arthritis Rheum 2012; 64: 3666-3676.
50. Thurlings RM, Boumans M, Tekstra J, et al. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum 2010; 62:3607-3614.
51. Raterman HG, Vosslamber S, de Ridder S, et al. The interferon type I signature towards prediction of nonresponse to rituximab in rheumatoid arthritis patients. Arthritis Res Ther 2012; 14:R95.
52. Park JK. Rheumatoid arthritis subgroup with type I interferon signature: comment on the article by Thurlings et al. Arthritis Rheum 2011; 63:4033.